These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19704343)

  • 1. Acute renal failure in a patient receiving anti-VEGF therapy for advanced non-small cell lung cancer.
    Zhao J; Li H; Wang M
    J Thorac Oncol; 2009 Sep; 4(9):1185-7. PubMed ID: 19704343
    [No Abstract]   [Full Text] [Related]  

  • 2. Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy.
    Gore E; Currey A; Choong N
    J Thorac Oncol; 2009 Dec; 4(12):1590-1. PubMed ID: 20009916
    [No Abstract]   [Full Text] [Related]  

  • 3. Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab.
    Tanvetyanon T; Murtagh R; Bepler G
    J Thorac Oncol; 2009 Feb; 4(2):268-9. PubMed ID: 19179909
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab-induced hypertension: pathogenesis and management.
    Syrigos KN; Karapanagiotou E; Boura P; Manegold C; Harrington K
    BioDrugs; 2011 Jun; 25(3):159-69. PubMed ID: 21627340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
    Frangié C; Lefaucheur C; Medioni J; Jacquot C; Hill GS; Nochy D
    Lancet Oncol; 2007 Feb; 8(2):177-8. PubMed ID: 17267332
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bevacizumab and arterial hypertension or proteinuria: management].
    Senellart H; Bennouna J
    Rev Mal Respir; 2008 Jun; 25(6):767-72. PubMed ID: 18772832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma.
    Roncone D; Satoskar A; Nadasdy T; Monk JP; Rovin BH
    Nat Clin Pract Nephrol; 2007 May; 3(5):287-93. PubMed ID: 17457362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Targeted therapies. New hopes, new challenges].
    Barlési F
    Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab.
    Katsenos S; Christophylakis C; Psathakis K
    Arch Bronconeumol; 2012 Jun; 48(6):218-9. PubMed ID: 22429334
    [No Abstract]   [Full Text] [Related]  

  • 12. Complete regression of a non-small cell lung cancer choroidal metastasis with intravitreal bevacizumab.
    D'Antonio C; Viterbo A; Romiti A; Enrici MM; Lauro S; Marchetti P
    J Thorac Oncol; 2012 Feb; 7(2):468-9. PubMed ID: 22252564
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab in lung cancer: hurdles in clinical development.
    Pirker R
    Lancet Oncol; 2010 Aug; 11(8):703-4. PubMed ID: 20650687
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficacy and tolerance of bevacizumab in non-small cell lung cancer: preliminary report].
    Mazières J; Dansin E
    Rev Pneumol Clin; 2008 Aug; 64(4):166-72. PubMed ID: 19019283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
    Klamerus JF; Brahmer JR
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
    Kelly K; Huang C
    J Thorac Oncol; 2008 Jun; 3(6):664-73. PubMed ID: 18520811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
    Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
    N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of bevacizumab for the treatment of non-small-cell lung cancer.
    Ramalingam S; Belani CP
    Future Oncol; 2007 Apr; 3(2):131-9. PubMed ID: 17381412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.